Imax is a must for movie theaters, making the stock a buy, Morgan Stanley says
Morgan Stanley initiated coverage of Imax with an overweight rating and a $63 price target, suggesting 18% upside. The bank cites Imax's growing network, film slate, and box office revenue growth. Imax's box office is projected to reach $1.7 billion in 2028, up from $1.5 billion in 2026. The success of 'The Odyssey' highlights the value of Imax's technology and brand. 12 of 14 analysts rate Imax a buy or strong buy, and shares are up 21% over the past three months.
How this was made
The 30-second read
Why it matters
The new analyst coverage adds a fresh catalyst that could translate into short‑term price appreciation.
Market read
Analyst initiation and price target provide a clear, actionable bullish signal for IMAX stock.
What to watch
Potential supply‑chain constraints for IMAX equipment and the high cost of theater upgrades.
Background
IMAX has been expanding its premium screen footprint and recently saw a blockbuster film shot entirely on its format.
Ticker impact
Morgan Stanley initiated coverage with an overweight rating and a $63 price target, indicating a fresh bullish catalyst.
Potential 5-10% price increase over the next weeks as investors absorb the new rating.
Coverage initiation is a primary disclosure; the firm’s bullish thesis and target provide a clear actionable signal.
Market effects
Positive outlook for premium cinema technology may lift peers in the entertainment exhibition sector.
U.S. cinema operators could see increased foot traffic, modestly supporting related REITs.
IMAX’s global network may benefit from worldwide premium content trends.
Counterpoint
The rating may be premature if box‑office growth stalls or streaming competition intensifies.
Key entities
- AnalystMorgan Stanley
Investment bank that initiated coverage with an overweight rating.
- AnalystDaniel Duran
Morgan Stanley analyst authoring the note.
